Seattle Genetics Shows Re-Treatment Action
Seattle Genetics (NASDAQ: SGEN) and Cambridge, MA-based Millennium: The Takeda Oncology Company said today that their “empowered antibody” for blood cancers showed promising results in a small study of patients who were re-treated following a relapse. The study found that seven of 11 patients with Hodgkin’s disease or anaplastic large cell lymphoma had at least partial tumor shrinkage after getting re-treated with brentuximab vedotin. The drug is unusual in that it combines the targeting ability of an antibody with a toxin to make it more potent against tumors. Results were presented today at the American Society of Clinical Oncology meeting in Chicago. We wrote a detailed story last month about the commercial potential Seattle Genetics and Millennium see in this emerging field of cancer treatment.